In this issue, Holmannova and co-workers present the results of their investigation into the one aspect of the inflammatory response to cardiac surgery undertaken using either conventional or miniaturised cardiopulmonary bypass (CPB). 1 Given the results of previous work in this area, it may not come as a surprise to find more evidence that the inflammatory response can be reduced by the newer technique and reducing the inflammatory response is obviously a good thing. Well … isn't it?
There are many different ways to modulate the inflammatory response, but none are unambiguously associated with improved patient outcomes. Few would deny that an excessive inflammatory response is harmful, but there is no good evidence to support the hypothesis that reducing the routine inflammatory response benefits adult patients. While the inflammation is probably responsible for leaky capillaries and reduced systemic vascular resistance, the cure can be worse than the disease. Perhaps the reduction in postoperative atrial fibrillation (AF) associated with perioperative steroid administration is due to suppression of inflammation (although the large SIRS trial failed to demonstrate any benefit with 0.5 g methylprednisolone 2 ), but the translation to improved outcome has not been demonstrated. A reduced inflammatory response has been one of the purported benefits of OPCAB (off-pump coronary bypass) surgery, but, as an indifferent observer (an anaesthetist), I do not see the 'obvious' clinical benefits seen by OPCAB surgeons and I'm still waiting for convincing evidence to turn up in print. The main reason for not acting on the plausible assumption that suppression of the inflammatory response is a good thing is that the means of suppression may have occasional, serious, adverse effects that outweigh the more common, modest benefits. For instance, fear of hyperglycaemia and gastrointestinal bleeding has moderated enthusiasm for steroids and aprotinin has been under a cloud in recent years in spite of its undoubted action of reducing the inflammatory response to bypass. I see many similarities between the status of miniature-CPB and of OPCAB. No-one thinks that conventional CPB is intrinsically good for people and no one would want it as an isolated procedure -it is only used because it allows essential surgery to be undertaken. It seems to makes sense to avoid it altogether by practicing OPCAB or to minimise the adverse effects by using miniaturised CPB. Unfortunately, early enthusiasm for OPCAB was detrimental to patients because of inadequate revascularisation and I find claims of superiority over conventional, on-pump CABG (coronary artery bypass grafting) unconvincing on currently available evidence. The track record of miniature-CPB is too short to be able to say that catastrophic events are no more common than when a conventional circuit is used and such events would not have to be common in order to outweigh any benefits associated with a reduced inflammatory response. It is a common observation that there is an urgent need for a large, randomised, controlled trial of miniature versus conventional CPB to identify differences in clinically important outcomes.
There is another approach to calming the inflammatory response to CPB. Since its first description in this journal over 25 years ago, modified ultrafiltration has been extensively used in paediatric perfusion to remove inflammatory mediators and reduce fluid overload after CPB. However, over the intervening years, the world of paediatric perfusion has been adopting changes in practice that are exactly analogous to the principles of miniature-CPB in the adult world. Could this circuit miniaturization have reduced inflammatory cytokines and haemodilution enough to negate the need for modified ultrafiltration, which is not without adverse effects of its own? In this issue of Perfusion, McRobb and co-workers report on exactly that. 3 They have, indeed, been able to omit modified ultrafiltration without detriment to their patients.
Although modified ultrafiltration has not been adopted into adult perfusion practice, it has had its advocates and there is a little evidence to support its use. 4 The problems in adult perfusion were not generally deemed sufficient to introduce modified ultrafiltration, a new procedure which adds complexity and has potential adverse effects of its own. That does not mean that the problems should be ignored -perhaps they can be avoided by adopting miniaturised CPB. It Bypass and inflammation 691404P RF0010.1177/0267659117691404PerfusionEditorial editorial2017 Editorial is, after all, only a modification of existing systems, not an addition. I think the reports in this issue of Perfusion will add a few grains to the scales, weighing opinion in favour of the value of miniature-CPB.
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